These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor
preprintrevised on 21.03.2021, 16:04 and posted on 23.03.2021, 06:21 by Anna Skwarska, Ewen Calder, Deborah Sneddon, Hannah Bolland, Maria Odyniec, Ishna N. Mistry, Jennifer Martin, Lisa Folkes, Ester M. Hammond, Stuart Conway
Tumor hypoxia is associated with therapy resistance and poor patient prognosis. Hypoxia-activated prodrugs, designed to selectively target hypoxic cells while sparing normal tissue, represent a promising treatment strategy. We report the pre-clinical efficacy of 1-methyl-2-nitroimidazole panobinostat (NI-Pano, CH-03), a novel bioreductive version of the clinically used lysine deacetylase inhibitor, panobinostat. NI-Pano was stable in normoxic (21% oxygen) conditions and underwent NADPH-CYP-mediated enzymatic bioreduction to release panobinostat in hypoxia (<0.1% oxygen). Treatment of cells grown in both 2D and 3D with NI-Pano increased acetylation of histone H3 at lysine 9, induced apoptosis and decreased clonogenic survival. Importantly, NI-Pano exhibited growth delay effects as a single agent in tumor xenografts. Pharmacokinetic analysis confirmed the presence of sub- micromolar concentrations of panobinostat in hypoxic mouse xenografts, but not in circulating plasma or kidneys. Together, our preclinical results provide a strong mechanistic rationale for the clinical development of NI-Pano for selective targeting of hypoxic tumors.
Chemical bioreductive approaches to targeted radiosensitisation and imaging of tumours
Medical Research CouncilFind out more...
Chemical biology tools for investigating the chemistry of cellular REDOX stress
Engineering and Physical Sciences Research CouncilFind out more...